Drugs / VGX-100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01514123 | Dec 2011 → Feb 2014 | cancer | Circadian Technologies Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VGX-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01514123 ↗ |
| Modality | Monoclonal antibody | “VEGF-C human monoclonal antibody VGX-100” NCT01514123 ↗ |
| Route | Intravenous | “VGX-100 will be administered by IV infusion once every week” NCT01514123 ↗ |
| Target | VEGFC | “VEGF-C human monoclonal antibody VGX-100” NCT01514123 ↗ |